Source:

Press release

Disclosures: Kereiakes reports consulting for Boston Scientific, Caliber Therapeutics/Orchestra BioMed, Elixir Medical, Shockwave Medical, Sino Medical Sciences Technologies and Svelte Medical Systems and holding equity in Ablative Solutions. Rao reports receiving research grants from Amgen, Bayer, Shockwave Medical and Svelte Medical.
December 15, 2021
1 min read
Save

DES systems to facilitate transradial PCI receive FDA approval

Source:

Press release

Disclosures: Kereiakes reports consulting for Boston Scientific, Caliber Therapeutics/Orchestra BioMed, Elixir Medical, Shockwave Medical, Sino Medical Sciences Technologies and Svelte Medical Systems and holding equity in Ablative Solutions. Rao reports receiving research grants from Amgen, Bayer, Shockwave Medical and Svelte Medical.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Svelte Medical Systems announced the FDA approved two of its drug-eluting stent systems designed to facilitate transradial PCI.

The systems (Slender IDS and Direct RX, Svelte) incorporate a stent, a bioresorbable drug coating and a balloon technology and are approved to treat patients with CAD, according to a press release issued by the company.

fdaapproval
Source: Adobe Stock

Slender IDS has an integrated delivery system featuring a guidewire technology from Asahi Medical, and Direct RX is a rapid-exchange delivery system, and both are low-profile systems designed to enhance transradial PCI and are indicated for direct stenting, according to the release.

The approval was based on the OPTIMIZE IDE trial, in which the systems had a 1-year rate of target lesion revascularization of 1.5%, the lowest reported for an investigational DES, the company stated in the release.

Dean Kereiakes

“Slender IDS and Direct RX are extremely low profile, highly deliverable DES systems that provide excellent early and long-term clinical outcomes in complex patient populations,” Dean Kereiakes, MD, FACC, FSCAI, president of The Christ Hospital Heart & Vascular Institute in Cincinnati, clinical professor of medicine at The Ohio State University and co-principal investigator of the OPTIMIZE study, said in the release. “Slender IDS uses a unique DES delivery platform while both systems incorporate a novel drug carrier and other technologies, which I believe will add value in the treatment of patients in the U.S.”

Sunil Rao

“Materially lower system and crossing profiles facilitate transradial intervention, which, when combined with a direct stenting approach in appropriate clinical indications, streamline procedures, limit complications and enhance patient experience,” Sunil Rao, MD, FSCAI, FACC, professor of medicine at Duke University and co-principal investigator of the OPTIMIZE study, said in the release. “Transradial intervention has been long regarded as the standard of care overseas. With its increased adoption and use in the majority of cases recently in the U.S., approval of these products is very timely. I am excited to integrate them into my practice.”